Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-trans Retinoic Acid in Primary Immune Thrombocytopenia
NCT07597395Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tretinoin in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
tretinoin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07597395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597395.